Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 577,447,000, a decrease of 11.2% compared to RMB 649,920,000 in 2023[9] - Gross profit for the same period was RMB 337,912,000, down 6.6% from RMB 361,849,000, with a gross profit margin of 58.5%, an increase of 2.8 percentage points from 55.7%[9] - Profit before tax increased by 70.2% to RMB 556,752,000, compared to RMB 327,211,000 in the previous year[9] - Profit for the period attributable to owners of the parent rose by 92.6% to RMB 493,046,000, up from RMB 255,941,000 in 2023[9] - Net profit margin improved significantly to 85.4%, up 46 percentage points from 39.4%[9] - Basic earnings per share increased by 92.5% to RMB 0.3286, compared to RMB 0.1707 in the prior year[9] - The interim dividend per share remained at HK$0.015, consistent with the previous year[9] - The gain on disposal of an associate was RMB 286,670,000, which was not applicable in the previous year[9] Research and Development - The Group established the "Suzhou Dawnrays Advanced Technology Research Institute" to enhance its R&D capabilities and improve product development processes[19] - The Group will continue to invest more resources in R&D and innovation of production technology and products, seeking various cooperation opportunities to optimize product mix and profitability[19] - Research and development expenses increased by approximately RMB 13,122,000 to approximately RMB 43,883,000 compared to the same period last year[37] - The Group focuses on the research and development of difficult-to-generate, first-to-market, and innovative drugs to achieve synergistic development of generic and innovative drugs[32] Market and Sales Performance - The sales volume and amount of the Group's anti-hypertensive drug "An" series decreased by 2.8% and 18.4% respectively, due to the impact of national centralized procurement[16] - The sales volume of Fujian Dawnrays series products increased by 11.2%, while the sales amount increased by 4.3% compared to the same period of last year[16] - The sales volume and amount of cephalosporin intermediates and bulk medicines decreased by 88.3% and 84.9% respectively, compared to the same period of 2023[16] Financial Position - As of June 30, 2024, net assets attributable to owners of the parent were approximately RMB 3,271,104,000, with a return on net assets of 15.1%, up from 9.1% in 2023[44] - The current ratio and quick ratio were reported at 3.40 and 3.04 respectively[46] - Total assets as of June 30, 2024, amounted to RMB 4,044,544,000, up from RMB 3,622,659,000 as of December 31, 2023[107] - Total equity attributable to owners of the parent increased to RMB 3,271,104,000 as of June 30, 2024, from RMB 2,859,234,000 at the end of 2023, representing a growth of 14.4%[87] Cash Flow and Liquidity - The net cash flows from operating activities were approximately RMB 171,454,000, compared to RMB 192,470,000 in 2023, while cash and cash equivalents increased by approximately RMB 169,211,000[49] - Cash and bank balances rose significantly to RMB 1,132,322,000 from RMB 905,826,000, marking an increase of 25.0%[85] - The total cash flows from operating activities for the six months ended June 30, 2024, were RMB 349,621,000, compared to RMB 260,216,000 for the same period in 2023, reflecting an increase of approximately 34%[91] Shareholder Information - The Group's share capital includes 704,304,000 shares held by Ms. Li Kei Ling and Mr. Hung Yung Lai, representing approximately 46.94% and 39.91% of the issued share capital, respectively[69] - Fortune United Group Limited holds 596,932,000 shares, representing approximately 39.78% of the company's issued share capital[78] - The company declared an interim dividend of HK$0.015 per share, totaling approximately HK$22,506,000 (around RMB 20,594,000)[82] Compliance and Governance - The interim results have been reviewed by the audit committee of the Company, ensuring accuracy and compliance[8] - The interim financial statements have not been audited and were approved by the Board on August 23, 2024[97] - The company maintains compliance with regulatory requirements regarding shareholder interests and disclosures[79] Risk Management - The Group's financial risk management objectives include minimizing exposure to foreign currency and credit risks while maintaining liquidity[161] - Interest rate risk primarily arises from borrowings, with the Group managing this risk through fixed rate borrowing and interest rate swaps[165] - The Group continues to assess credit risk by grouping other receivables into Stage 1 and Stage 2, with Stage 1 allowing for a 12-month expected credit loss (ECL) provision[162]

Revenue and Profitability - Revenue for the six months ended June 30, 2024, was RMB 577,447 thousand, a decrease of 11.2% compared to RMB 649,920 thousand in the same period of 2023[4] - Gross profit for the same period was RMB 337,912 thousand, down 6.6% from RMB 361,849 thousand, with a gross margin of 58.5%, an increase of 2.8 percentage points year-on-year[4] - Profit before tax increased by 70.2% to RMB 556,752 thousand from RMB 327,211 thousand in the previous year[5] - Net profit attributable to the owners of the parent company rose by 92.6% to RMB 493,046 thousand, compared to RMB 255,941 thousand in the prior year[4] - Basic earnings per share increased by 92.5% to RMB 0.3286 from RMB 0.1707 in the same period last year[5] - The company reported other income and gains of RMB 421,636 thousand, significantly up from RMB 162,927 thousand in the previous year[5] - The profit attributable to equity holders of the parent company for the same period was approximately RMB 493,046,000, an increase of 92.6% from RMB 255,941,000 in 2023[31] - The main reason for the profit increase was the net gain from the sale of a 35% stake in Kangrong Dongfang amounting to approximately RMB 277,627,000[45] Assets and Liabilities - Total assets less current liabilities amounted to RMB 3,388,691 thousand, compared to RMB 2,953,719 thousand at the end of 2023[7] - Cash and bank deposits increased to RMB 1,132,322 thousand from RMB 905,826 thousand at the end of 2023[7] - The company’s total liabilities as of June 30, 2024, were RMB 4,044,544 thousand, indicating a significant increase from the previous reporting period[18] - As of June 30, 2024, the net assets attributable to the parent company were approximately RMB 3,271,104,000, with a return on equity of 15.1%, up from 9.1% in the previous year[46] - The group’s total liabilities ratio was 4.5% as of June 30, 2024, compared to 3.3% at the end of the previous year[49] Revenue Breakdown - The revenue from external sales in the "Finished Drugs" category was RMB 560,878 thousand, while the "Intermediates and Raw Materials" category generated RMB 16,569 thousand for the six months ended June 30, 2024[17] - Total revenue from customer contracts reached RMB 577,447,000, with pharmaceutical product sales contributing RMB 577,416,000[20] - The group’s total revenue from the Chinese market was RMB 574,210,000, with additional revenue from other countries amounting to RMB 3,237,000[20] - Sales of finished drugs amounted to approximately RMB 560,878,000, an increase of 3.8% from RMB 540,313,000 year-on-year, representing 97.1% of total sales, up 14 percentage points[41] Research and Development - Research and development costs for the current period were RMB 37,047,000, up from RMB 27,004,000 in the same period last year[23] - The company established the "Suzhou Dongrui Advanced Technology Research Institute" to enhance R&D capabilities and improve product development efficiency[34] - The group plans to enhance its R&D capabilities and focus on chronic disease management, leveraging resources from its advanced technology research institutes[39] - R&D expenses increased by approximately RMB 13,122,000 to RMB 43,883,000, reflecting a focus on innovation and development[42] Dividends and Shareholder Returns - The company maintained an interim dividend of HKD 0.015 per share, unchanged from the previous year[4] - The company declared a final dividend of RMB 90,786,000 for the fiscal year, with an interim dividend of RMB 20,594,000 for the six months ended June 30, 2024[25] - The diluted earnings per share for the same period was RMB 0.3282, up from RMB 0.1702 in 2023[27] Operational Performance - The company’s management is closely monitoring operational performance across its product categories to make informed resource allocation decisions[16] - The company plans to continue optimizing its structure and expanding its market presence, focusing on the development and sales of non-patented drugs[16] - The company aims to establish broader partnerships with chain pharmacies and explore diversified business models, including online sales through e-commerce[39] Financial Reporting and Compliance - The financial statements were prepared in accordance with International Financial Reporting Standards and are unaudited[12] - The company has adopted new accounting policies in line with the latest International Financial Reporting Standards, impacting the financial reporting for the current period[15] - The group has complied with the corporate governance code as per the Hong Kong Stock Exchange rules, with the exception of two independent non-executive directors who were unable to attend the annual general meeting[57] Market Conditions and Future Outlook - The pharmaceutical industry is experiencing strong growth driven by technological innovation and increasing health awareness post-pandemic[32] - The group has no significant investments or acquisitions of subsidiaries or associates during the period, but has sufficient financial resources to cover planned capital expenditures[50] - There are no major investment plans or capital asset acquisitions disclosed for the future, aside from capital expenditures related to subsidiary capital increases and relocation projects[55]

Financial Performance - Revenue for the year ended December 31, 2023, was RMB 1,151,145 thousand, a decrease of 9.9% compared to RMB 1,277,682 thousand in 2022[1]. - Gross profit decreased by 17.1% to RMB 641,519 thousand, with a gross margin of 55.7%, down from 60.5% in the previous year[1]. - Profit attributable to equity holders of the parent was RMB 326,000 thousand, representing a decline of 9.0% from RMB 358,057 thousand in 2022[1]. - Basic earnings per share decreased by 9.0% to RMB 0.2174, down from RMB 0.2389 in the prior year[1]. - The proposed final dividend per share is HKD 0.065, a decrease of 11.0% from HKD 0.073 in 2022[1]. - The adjusted profit before tax for the year 2023 was RMB 414,057,000, a decrease from RMB 438,408,000 in 2022, representing a decline of approximately 5.3%[31]. - The company's profit for the year ended December 31, 2023, was RMB 322,667,000, a decrease of 9.3% compared to RMB 355,851,000 in 2022[86]. - Total comprehensive income for the year, after tax, was RMB 326,292,000, down from RMB 364,256,000 in the previous year, reflecting a decline of 10.4%[86]. - The company's equity attributable to owners of the parent increased to RMB 2,854,656,000 in 2023 from RMB 2,641,956,000 in 2022, representing a growth of 8.0%[88]. - The company's total equity as of December 31, 2023, was RMB 2,859,234,000, compared to RMB 2,649,867,000 in 2022, indicating an increase of 7.9%[88]. Assets and Liabilities - Non-current assets totaled RMB 1,902,463 thousand, slightly down from RMB 1,928,648 thousand in the previous year[5]. - Current assets decreased to RMB 1,720,196 thousand from RMB 1,743,995 thousand, with cash and bank deposits increasing to RMB 905,826 thousand from RMB 811,682 thousand[5]. - Total liabilities decreased to RMB 94,485 thousand from RMB 90,719 thousand, reflecting improved financial stability[5]. - The total assets as of December 31, 2023, amounted to RMB 3,622,659 thousand, a decrease from RMB 3,672,643 thousand in 2022[97]. - The total liabilities as of December 31, 2023, were RMB 763,425 thousand, down from RMB 1,022,776 thousand in 2022, indicating a significant reduction of 25.4%[97]. Research and Development - Research and development costs rose to RMB 90,808 thousand, compared to RMB 79,478 thousand in 2022, indicating increased investment in innovation[3]. - Research and development costs for the year totaled RMB 84,611,000, compared to RMB 74,799,000 in 2022, marking an increase of approximately 13%[39]. - The company established the Suzhou Dongrui Advanced Technology Research Institute in April 2023 to optimize R&D resources, with 59% of current R&D projects being self-developed[65]. - The company is focusing on developing generic drugs and improved innovative drugs, with a strategy to prepare for the next round of bidding[65]. - The company plans to increase R&D investment and upgrade production facilities to accelerate the launch of new products[68]. Sales and Market Performance - The company experienced a decline in sales volume for certain products due to competitive bidding, with sales for the "An" series products decreasing by 22.8% compared to the same period in 2022[64]. - Sales of antihypertensive products amounted to RMB 424,186,000 in 2023, down from RMB 549,229,000 in 2022, accounting for 36.8% of total sales[130]. - Antihyperlipidemic products generated sales of RMB 292,331,000 in 2023, compared to RMB 310,502,000 in 2022, representing 25.4% of total sales[131]. - Antiviral products achieved sales of RMB 124,828,000 in 2023, a slight decrease from RMB 133,005,000 in 2022, making up 10.8% of total sales[132]. - The sales volume of the hypertension treatment product series decreased by 28.1%, with sales revenue down by 22.8% compared to 2022[186]. - The sales volume of the anti-allergy drugs "Xikewei" and "Xikexin" decreased by 16.1%, with sales revenue down by 22.6% compared to the previous year[186]. - The sales volume of the antiviral drug Entecavir dispersible tablets increased by 3.2%, but sales revenue decreased by 6.2% compared to the previous year[186]. Dividends and Shareholder Returns - The mid-term dividend per ordinary share for 2023 was HKD 0.015, consistent with 2022, while the proposed final dividend decreased to HKD 0.065 from HKD 0.073 in 2022[43]. - The group proposed a final dividend of HKD 0.065 per share, bringing the total dividend for the year to HKD 0.08 per share, with a payout ratio of approximately 34.0%, an increase of 1.6 percentage points year-on-year[53]. - The board proposed a final dividend of HKD 0.065 per share for the year ending December 31, 2023, totaling approximately HKD 97,516,000, down from HKD 109,412,000 in 2022[62]. - The company remains optimistic about its business development and aims to create reasonable investment returns for shareholders[68]. Operational Changes and Strategies - The group has completed the trial production phase at its new facilities, which is expected to enhance the production and supply of intermediates and active pharmaceutical ingredients[54]. - The group is actively expanding its export business and international presence, with ongoing customer registration and overseas registration efforts[54]. - The company is adapting to the national pharmaceutical development plan, aiming for high-quality development and integration in the pharmaceutical industry[63]. - The company is actively exploring new business models such as pharmaceutical e-commerce to enhance profitability[188]. - The company plans to expand new product market development and strengthen cooperation with chain pharmacies to drive sales growth in 2024[188]. Financial Management and Risks - The company has implemented a rigorous credit monitoring system to manage credit risk, with no significant concentration of credit risk among its diverse customer base[48]. - The expected credit loss rate increased to 2.30% in 2023 from 1.37% in 2022, with total carrying amount of RMB 155,967,000[57]. - The company reported a foreign exchange loss of RMB 2,679,000 from overseas operations, an improvement from a loss of RMB 10,414,000 in the previous year[86]. - The group recorded a foreign exchange loss of RMB 5,526,000 for the year, compared to a gain of RMB 4,537,000 in 2022[167]. - The company has no income tax obligations due to tax exemptions in the Cayman Islands, effective for 20 years from October 8, 2002, and renewed for another 20 years from September 19, 2023[124]. Capital Expenditure and Investments - Capital expenditure for the year was RMB 231,269,000, compared to RMB 92,483,000 in the previous year[114]. - The group invested RMB 20,000,000 to hold a 1.48% stake in China-U.S. Huashitong Biomedical Technology Co., Ltd.[161]. - The group received RMB 175,595,000 in compensation for the relocation of its Suzhou facility, with a total planned investment of RMB 519,799,000 for the new site[163]. - Employee costs increased to approximately RMB 211,780,000 from RMB 183,630,000, reflecting an increase in headcount and salary adjustments[168].

Financial Performance - For the six months ended June 30, 2023, the total revenue was RMB 649,920,000, with external sales of finished drugs at RMB 540,313,000 and intermediates at RMB 109,607,000[17]. - The segment results showed a profit before tax of RMB 327,211,000, compared to RMB 225,591,000 for the same period in 2022, indicating a year-over-year increase of approximately 45%[17]. - The company reported unallocated gains of RMB 158,150,000, while corporate and other unallocated expenses were RMB 108,665,000, leading to a net profit before tax after adjustments[17]. - The company’s external sales to customers decreased from RMB 568,544,000 in the previous year to RMB 540,313,000, reflecting a decline of approximately 5%[17]. - The company’s segment results for finished drugs showed a profit of RMB 290,301,000, while intermediates reported a loss of RMB 12,269,000[17]. - The group reported a profit before tax of RMB 96,929,000 for the six months ended June 30, 2023, compared to RMB 75,350,000 in 2022, indicating a growth of approximately 28.7%[49]. - Revenue from contracts with customers for the six months ended June 30, 2023, was RMB 649,920,000, representing an increase from RMB 623,478,000 in the same period of 2022[29]. Revenue Breakdown - Revenue from Mainland China was RMB 537,134,000, accounting for the majority of total revenue from contracts with customers[29]. - The finished drugs segment generated revenue of RMB 540,307,000, while the intermediates and bulk medicines segment contributed RMB 109,607,000 for the six months ended June 30, 2023[29]. - The total segment revenue for the six months ended June 30, 2022, was RMB 623,478,000, indicating a decrease in overall sales compared to the current period[17]. - Total revenue from contracts with customers for the six months ended June 30, 2023, was RMB 623,478,000, a slight increase from RMB 623,302,000 in 2022[33]. - Revenue from pharmaceutical goods sales was RMB 623,302,000, contributing significantly to total revenue[33]. Costs and Expenses - Cost of sales increased to RMB 288,071,000 in 2023 from RMB 231,200,000 in 2022, reflecting a rise of about 24.6%[49]. - Research and development costs for the period amounted to RMB 30,761,000, slightly up from RMB 29,960,000 in 2022[49]. - Other income for the six months ended June 30, 2023, was RMB 16,452,000, down from RMB 21,305,000 in 2022[37]. - The depreciation of property, plant, and equipment was RMB 31,751,000 in 2023, compared to RMB 22,446,000 in 2022, representing a significant increase of about 41.5%[49]. - The company incurred finance costs of RMB 27,333,000 for lease liabilities, up from RMB 43,225,000 in 2022, indicating a decrease in financial burden[39]. Taxation - Current income tax charge increased to RMB 75,699, up 90.2% from RMB 39,801 in the previous year[60]. - Total tax charge for the period reached RMB 73,041, representing a 36.0% increase compared to RMB 53,765 in 2022[60]. Assets and Liabilities - As of June 30, 2023, the total assets of the Group amounted to RMB 3,557,356,000, a decrease from RMB 3,672,643,000 as of December 31, 2022[19][24]. - The Group's segment assets for finished drugs were RMB 908,319,000 and for intermediates and bulk medicines were RMB 1,192,678,000 as of June 30, 2023[19]. - The assets held for sale amounted to RMB 2,578,000 as of June 30, 2023[19]. - Trade and notes receivables decreased to RMB 193,431 from RMB 204,324, a decline of 5.0%[64]. - Cash and bank balances decreased to RMB 741,149 from RMB 811,682, a reduction of 8.7%[64]. Financial Instruments and Risks - The Group's financial instruments are exposed to foreign currency risk, credit risk, liquidity risk, and interest rate risk[79]. - The Group has no significant credit risk concentration from third-party debtors, with maximum exposure to credit risk represented by cash, bank balances, and trade receivables[79]. - The expected loss allowance provision for trade receivables was not material during the period ended June 30, 2023[83]. - The Group's management believes the risk of default by counterparties is low[83]. Share Capital and Dividends - For the six months ended June 30, 2023, profit attributable to ordinary equity holders of the parent was RMB 255,941,000, an increase of 49% compared to RMB 171,661,000 in 2022[99]. - Basic earnings per share for the period was RMB 0.1707, up from RMB 0.11456 in the same period last year, reflecting a growth of approximately 49%[99]. - The company declared an interim dividend of HK$0.015 per share, totaling approximately HK$22,497,000 (approximately RMB 20,986,000) for the year ending December 31, 2023[94]. - The issued and fully paid ordinary shares increased from 1,498,789,000 at the beginning of the period to 1,499,793,000 at the end of the period[178]. Share Option Scheme - The 2023 Share Option Scheme allows for a total of 149,970,500 shares to be issued, which is 10% of the total shares in issue on the adoption date[182]. - The Chief Executive Officer holds 6,000,000 share options, which are exercisable from 29 April 2023 to 28 April 2028[188]. - The total number of options available for grant under the 2023 Share Option Scheme remained at 149,970,500 at both the adoption date and the end of the period[182]. - The total number of options available for grant under the service provider sublimit was 7,498,525 at both the adoption date and the end of the period[182]. - For the six months ended June 30, 2023, no share options were cancelled[190].

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 649,920,000, representing a 4.2% increase from RMB 623,478,000 in the same period of 2022[6] - Gross profit decreased to RMB 361,849,000, down 7.8% from RMB 392,278,000, resulting in a gross margin of 55.7%, a decline of 7.2 percentage points[6] - Profit before tax increased by 45.0% to RMB 327,211,000 compared to RMB 225,591,000 in the previous year[6] - Net profit attributable to shareholders rose by 49.1% to RMB 255,941,000 from RMB 171,661,000[6] - Basic earnings per share increased by 49.0% to RMB 0.1707, compared to RMB 0.11456 in the prior period[6] - The company reported a profit margin improvement, with the adjusted profit margin before tax increasing to approximately 50.3% for the first half of 2023, compared to 36.2% for the same period in 2022[23] - The increase in profit was primarily due to the after-tax government compensation of RMB 115,984,000 related to the disposal of the Suzhou Dongrui Pharmaceutical Co., Ltd. factory[81] - Excluding this non-recurring item, the profit for the period was RMB 139,957,000, a decrease of RMB 31,704,000 or 18.5% compared to the previous year[81] Assets and Liabilities - Total assets decreased to RMB 1,896,691,000 from RMB 1,928,648,000, while total liabilities also decreased, indicating improved asset management[13] - The company reported a net current asset of RMB 1,018,759,000, an increase from RMB 811,938,000, reflecting better liquidity[13] - As of June 30, 2023, total assets amounted to RMB 2,100,997,000, a decrease from RMB 2,219,731,000 as of December 31, 2022[24] - The company's net assets as of June 30, 2023, were approximately RMB 2,807,865,000, with a return on equity of 9.1%, up from 6.9% in 2022[96] - The total bank credit line was approximately RMB 1,075,000,000, down from RMB 1,370,000,000 at the end of 2022[100] - The group has no assets pledged to banks for credit facilities as of June 30, 2023[132] Dividends - The company maintained an interim dividend of HKD 0.015 per share, unchanged from the previous year[6] - The company declared an interim dividend of HKD 0.015 per share, totaling approximately HKD 22,497,000 (about RMB 20,986,000)[44] - The board declared an interim dividend of HKD 0.015 per share, totaling approximately HKD 22,497,000 (approximately RMB 20,986,000) for the year ending December 31, 2023[136] Research and Development - Research and development costs for the current year amounted to RMB 27,004,000, slightly down from RMB 28,746,000 in the previous year[47] - The group plans to enhance its R&D capabilities through the newly established Suzhou Dongrui Pharmaceutical Advanced Technology Research Institute, integrating resources for innovative drug development[112] - The group has invested a total of RMB 185,000,000 in its subsidiary Dongrui Biological for the development of two new drugs, with an additional RMB 120,143,000 in interest-bearing loans provided to a partner company[122] - The company has 32 products undergoing quality and efficacy consistency studies, with 14 applications already approved[55] - The company received 8 approvals during the first half of 2023, including 4 for chemical drugs and 2 for active pharmaceutical ingredients[57] Sales and Revenue Breakdown - Revenue from pharmaceutical products was RMB 540,313,000, while the revenue from intermediates and raw materials was RMB 109,607,000 for the six months ended June 30, 2023[38] - Revenue from contracts with customers in mainland China was RMB 641,017,000, accounting for the majority of total revenue for the six months ended June 30, 2023[38] - Sales revenue for the pharmaceutical segment accounted for approximately 83.1% of total sales, a decrease of 8.1 percentage points compared to the previous year[89] - Sales volume of the "An" series products decreased by 27.4% year-on-year, while sales revenue decreased by 10% due to the impact of national procurement[111] - Sales volume of cephalosporin intermediates and raw materials increased by 133.6%, with sales revenue increasing by 99.5% compared to the previous year[111] - Sales of traditional Chinese medicine amounted to RMB 540,313,000, a decrease of RMB 28,231,000 or 5% year-on-year, while sales of intermediates and raw materials increased by RMB 54,673,000 or 99.5% to RMB 109,607,000[117] Operational Performance - The management is closely monitoring operational performance by segment to make informed decisions regarding resource allocation and performance evaluation[21] - The average accounts receivable turnover period was approximately 56 days, with an increase of 17 days compared to the previous year, attributed to a decrease in the proportion of fast-receiving products[96] - The total employee costs for the period amounted to approximately RMB 96,929,000, an increase from RMB 75,350,000 in 2022, attributed to the commencement of production and verification at multiple facilities[131] - The group has completed the relocation of the Suzhou Dongrui Pharmaceutical facility and has commenced production in the solvent recovery workshop[128] - The group is focusing on optimizing its production conditions with the completion of two relocation projects, which will improve its industrial chain and create new growth drivers[116] Foreign Exchange and Other Financials - The company experienced a foreign exchange gain of RMB 14,172,000, compared to RMB 9,273,000 in the previous year, contributing positively to overall comprehensive income[10] - The company reported a net foreign exchange gain of RMB 6,205,000, up from RMB 3,346,000 in the previous year[47] - The group recorded a foreign exchange loss of RMB 6,205,000 during the period, compared to RMB 3,346,000 in 2022, primarily due to fluctuations in the RMB exchange rate related to associated company borrowings[130] - The group recorded a net gain of approximately RMB 3,484,000 from financial assets measured at fair value during the period, compared to RMB 3,979,000 in the previous year[125] Capital Expenditures - The company has committed but unprovided capital expenditures for property and machinery totaling approximately RMB 124,154,000 as of June 30, 2023, up from RMB 110,318,000 as of December 31, 2022[140] - The company has invested RMB 475,000,000 in a new production base for raw materials and intermediates, with the first phase already completed[102]

Financial Performance - For the year ended December 31, 2022, the Group recorded revenue of approximately RMB1,277,682,000, representing an increase of 9.7% compared to 2021[9]. - Profit attributable to owners of the parent was approximately RMB358,057,000, reflecting a slight decrease of 0.03% compared to 2021[9]. - Excluding certain losses, the operating profit would be RMB380,292,000, which is an increase of 13.5% compared to 2021[11]. - The total loss from the investment in AD Pharmaceuticals Co., Ltd. was RMB61,905,000, compared to RMB46,418,000 in 2021[11]. - The Group's overall sales in 2022 increased by 9.7% compared to the previous year, reaching approximately RMB 1,277,682,000[50]. - Gross profit was approximately RMB773,551,000, an increase of 13.5%, with a gross profit margin of 60.5%, up from 58.5% in the previous year[123]. - The intermediates and bulk medicines segment reported a loss of RMB17,775,000, worsening from a loss of RMB2,296,000 in 2021[128]. - Profit attributable to owners of the parent was approximately RMB358,057,000, a slight decrease of RMB118,000 or 0.03% compared to RMB358,175,000 in 2021[132]. - The actual operating profit attributable to owners of the parent, excluding certain factors, was RMB380,292,000, an increase of 13.5% compared to RMB335,085,000 in 2021[132]. Sales and Market Performance - The increase in revenue was primarily due to a significant rise in sales volume of products won in centralized procurement, including Atorvastatin Calcium Tablets and Entecavir Dispersible Tablets[19]. - The sales amount of specific medicines increased significantly year-on-year, driven by the rise in sales of Entecavir Dispersible Tablets and Atorvastatin Calcium Tablets, along with increased demand for anti-pandemic materials[30]. - The sales volumes and amounts of Telmisartan Tablets and Losartan Potassium and Hydrochlorothiazide Tablets experienced significant year-on-year growth[30]. - The sales volume and amount of Entecavir Dispersible Tablets increased by 19.5% and 47.0% respectively compared to the same period in 2021[46]. - The sales of the anti-hypertensive product series reached RMB 549,229,000, accounting for 43.0% of the Group's total sales, showing an increase from RMB 520,414,000 in 2021[76]. - The sales of anti-hyperlipidemic products amounted to RMB 270,368,000 in 2022, representing 21.2% of the Group's total sales, up from RMB 255,059,000 in 2021[77]. - The antiviral products generated sales of RMB 133,005,000 in 2022, which is a significant increase from RMB 90,503,000 in 2021, accounting for 10.4% of the Group's total sales[78]. Dividends and Shareholder Returns - The Board recommended a final dividend of HK$0.073 per share, totaling approximately HK$109,412,000, an increase from HK$0.065 per share in 2021[25]. - The final dividend is subject to approval at the forthcoming 2023 Annual General Meeting[25]. - The annual dividend for the year is HK$0.088 per share, with a payout ratio of approximately 32.4%, reflecting a year-on-year increase of 5.1 percentage points[29]. - The proposed final dividend is HKD 0.073 per share, up from HKD 0.065 the previous year, with a total payout of approximately HKD 109,412,000[50]. Organizational Changes and Strategy - The Group underwent a reorganization, transferring 100% share interest in Fujian Dawnrays Pharmaceutical Co., Ltd. and Lanzhou Dawnrays Pharmaceutical Co., Ltd. to Suzhou Dawnrays Pharmaceutical Co., Ltd.[16]. - The Group's financial results reflect a strategic focus on expanding its product offerings in the pharmaceutical sector[19]. - The restructuring of the organization aims to enhance efficiency and improve opportunities for winning bids in national centralized procurement activities[39]. - The Group's organizational restructuring in 2022 aimed to improve efficiency and facilitate unified control, which is expected to enhance brand recognition and support future international development[64]. - The Group plans to focus on the development of innovative drugs and improve its competitiveness in response to changes in the centralized procurement rules, which have intensified market competition[65]. Research and Development - The establishment of an advanced technology research institute in June 2022 aims to optimize R&D resources and attract external talent for drug development[36]. - The establishment of the "Suzhou Dawnrays Pharmaceutical Advanced Technology Research Institute" aims to integrate R&D teams and enhance the Group's research capabilities[86]. - The Group's ongoing R&D projects cover various therapeutic areas, including bio-pharmaceuticals and innovative drugs, with a focus on maximizing the benefits of research resources[85]. - As of December 31, 2022, the Group conducted quality and efficacy research into 31 varieties and submitted applications for consistency evaluation for 7 varieties to the Center for Drug Evaluation, NMPA[89]. - In 2022, the Group registered a total of 9 varieties, including 5 consistency evaluation approvals and 2 supplementary application approvals[92]. - The Group's pharmaceutical research into 10 varieties is ongoing, indicating a commitment to innovation and product development[89]. Financial Position and Investments - The Group's cash and bank balance was approximately RMB811,682,000, an increase from RMB577,744,000 as of December 31, 2021[162]. - The net cash inflows from operating activities for the year were approximately RMB434,266,000, compared to RMB393,139,000 in 2021, representing an increase of 10.5%[162]. - The Group's trade receivables increased by 16.0% to approximately RMB208,828,000 as of December 31, 2022, up from RMB180,017,000 in 2021, mainly due to increased sales[162]. - The inventory balance as of December 31, 2022, was approximately RMB241,746,000, an increase of RMB38,270,000 from RMB203,476,000 in 2021, primarily due to stocking of bulk medicines[163]. - The Group's debt ratio was 0.18% as of December 31, 2022, down from 0.6% in 2021, indicating improved financial stability[162]. - The Group's aggregate bank facilities amounted to approximately RMB1,370,000,000 as of December 31, 2022, compared to RMB1,100,000,000 in 2021[162]. - The Group's net cash outflows from investing activities were approximately RMB175,013,000 in 2022, a decrease from RMB284,202,000 in 2021[162]. Employee and Operational Metrics - The total employee count increased to approximately 1,106 in 2022 from 1,065 in 2021, with total remuneration rising to approximately RMB 183,630,000 from RMB 172,023,000[198]. - The increase in employee costs was primarily due to staff increase and salary adjustments[198]. - The Group's total expenses for the year were approximately RMB360,186,000, an increase of RMB28,786,000 from RMB331,400,000 in the previous year, accounting for 28.2% of turnover[152]. - The selling expense ratio for the year was 11.2%, reflecting an increase in selling expenses by RMB33,703,000 compared to the previous year[152].

Employee Costs and Workforce - As of December 31, 2022, the group had approximately 1,106 employees, with total employee costs amounting to RMB 183,630,000, an increase from RMB 172,023,000 in 2021[1]. - The total employee benefits expense, including salaries and wages, increased to RMB 183,630,000 in 2022 from RMB 172,023,000 in 2021, representing a growth of about 6.5%[128]. Financial Performance - The company's total sales for the year ended December 31, 2022, were approximately RMB 1,277,682,000, representing a growth of 9.7% year-on-year, with an increase of RMB 112,527,000[25]. - The revenue for the year ended December 31, 2022, was approximately RMB 1,277,682,000, representing a 9.7% increase from RMB 1,165,155,000 in 2021[59]. - The operating profit for the year was RMB 380,292,000, reflecting a 13.5% increase from RMB 335,085,000 in 2021[59]. - The net profit attributable to the owners of the parent company was RMB 358,057,000, slightly down by 0.03% from RMB 358,175,000 in the previous year[57]. - The company reported a pre-tax profit of RMB 438,408,000, a slight decrease of 0.2% from RMB 439,323,000 in 2021[59]. - The total comprehensive income for the year 2022, after tax, was RMB 364,256,000, compared to RMB 353,219,000 in 2021, indicating an increase of 3.0%[163]. Sales and Revenue Breakdown - The sales of finished drugs amounted to RMB 1,137,241,000, an increase of 12.7% compared to the previous year, accounting for approximately 89.0% of total sales, up by 2.4 percentage points[25][27]. - Revenue from pharmaceutical product sales was RMB 1,276,505,000 in 2022, compared to RMB 1,159,680,000 in 2021, indicating a year-over-year increase of about 10.1%[101]. - Revenue from external customers in mainland China for 2022 was RMB 1,218,740,000, up from RMB 1,102,806,000 in 2021, representing a growth of approximately 10.5%[86]. - The sales of specialty drugs showed significant year-on-year growth, driven by the continued rise in sales of Entecavir dispersible tablets and Atorvastatin calcium tablets[31]. - The sales volume of the antiviral drug Entecavir dispersible tablets grew by 19.5%, with revenue increasing by 47.0% year-on-year[39]. - The sales of atorvastatin calcium tablets reached RMB 270,368,000, up from RMB 255,059,000 in the previous year, making up 21.2% of total sales[41]. Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.073 per share, subject to shareholder approval at the annual general meeting on May 25, 2023[13]. - The company plans to distribute a final dividend of HKD 0.073 per share, totaling approximately HKD 109,412,000, which represents a payout ratio of about 32.4%, an increase of 5.1 percentage points year-on-year[28]. - The company declared a proposed final dividend of HKD 0.073 per share for 2022, compared to HKD 0.065 per share in 2021, reflecting an increase of about 12.3%[139]. Research and Development - In 2022, the group submitted registrations for 9 products to the National Medical Products Administration, including 7 supplementary applications and 1 active pharmaceutical ingredient registration[22]. - The company received two invention patents in 2022, enhancing its intellectual property portfolio[23]. - Research and development costs for the year were RMB 79,478,000, compared to RMB 67,028,000 in 2021[61]. - The establishment of the Advanced Technology Research Institute in June 2022 aims to optimize R&D resources and attract external talent for drug development[36]. - The company plans to accelerate its R&D, production, and sales efforts to adapt to national healthcare reforms and industry developments[37]. Assets and Liabilities - Total assets as of December 31, 2022, amounted to RMB 3,672,643,000, an increase from RMB 3,339,558,000 as of December 31, 2021[85]. - Total liabilities increased to RMB 1,012,776 thousand in 2022 from RMB 941,697 thousand in 2021, reflecting an increase of 7.5%[68]. - The company's total equity reached RMB 2,649,867 thousand in 2022, compared to RMB 2,397,861 thousand in 2021, indicating a growth of 10.5%[70]. - Current assets rose to RMB 1,743,995 thousand in 2022, up from RMB 1,511,036 thousand in 2021, marking an increase of 15.4%[68]. - Non-current assets increased to RMB 1,928,648 thousand in 2022 from RMB 1,828,522 thousand in 2021, representing a growth of 5.5%[68]. Operational Challenges - The company faced operational challenges due to the ongoing COVID-19 pandemic and geopolitical uncertainties, but maintained operations with the support of its employees[29]. - The sales of intermediates and raw materials decreased by 10.0% year-on-year to RMB 140,441,000, primarily due to the impact of the COVID-19 pandemic[25]. Investments and Future Plans - The group has no major future investment plans or capital asset purchases beyond disclosed capital expenditures and relocation plans[6]. - The company signed a shareholder loan agreement to provide a total of RMB 105,000,000 to 康融东方 in three installments to support project development[32]. - The company received government compensation of RMB 82,433,000 for the relocation of its antibiotic production facility[33]. - The company is optimistic about the future prospects of its investments based on clinical trial progress and market conditions[32]. Miscellaneous - The group had no significant contingent liabilities as of December 31, 2022[2]. - There were no assets pledged to banks for credit facilities as of December 31, 2022[3]. - The group reported a capital expenditure of RMB 231,269,000 for the year, compared to RMB 587,059,000 in the previous year[86]. - The company incurred a loss of RMB 61,905,000 from its investment in the joint venture 康融东方 due to high clinical trial costs[32].

Financial Performance - The Group recorded revenue of approximately RMB623,478,000 for the six months ended 30 June 2022, representing an increase of 2.4% compared to RMB608,589,000 in the same period of 2021[41]. - Profit attributable to owners of the parent was approximately RMB171,661,000, an increase of approximately 3.0% compared to RMB166,646,000 in the same period of 2021[41]. - The Group's overall sales increased by 2.4% in the first half of 2022 compared to the same period last year[68]. - For the six months ended June 30, 2022, the Group recorded a turnover of approximately RMB623,478,000, representing an increase of 2.4% compared to RMB608,589,000 during the corresponding period of last year[86]. - Gross profit was approximately RMB392,278,000, which increased by RMB19,187,000 or 5.1% compared to the corresponding period of last year[86]. - The gross profit margin improved to 62.9%, an increase of 1.6 percentage points from 61.3% in the previous year[86]. - Profit before tax increased to RMB 225,591,000, compared to RMB 211,082,000 in the prior year, representing a growth of 6.9%[177]. - The profit for the period attributable to owners of the parent was RMB 171,661,000, an increase from RMB 166,646,000, marking a growth of 3.0%[177]. - Total comprehensive income for the period, net of tax, rose to RMB 177,186,000, compared to RMB 167,377,000, reflecting an increase of 5.14%[180]. Sales and Market Performance - The overall sales of finished medicines increased by 7.0% compared to the same period last year, despite a 0.5% decrease in sales of the "An" series medicines due to centralized procurement impacts[47]. - Sales volume of Fujian Dawnrays series medicines, primarily for treating hyperlipidemia, rose by 26.5%, with sales revenue increasing by 19.4% year-on-year[68]. - The sales volume of cephalosporin intermediates and bulk medicines decreased by 46.0%, with sales revenue declining by 29.1% compared to the same period in 2021[68]. - The sales of anti-hypertensive drugs in the "An" series decreased by 1.0% in volume and 0.5% in revenue year-on-year[68]. Research and Development - The Advanced Technology Research Institute was established in June 2022 to integrate R&D resources and promote innovation within the Group[53]. - Clinical trials for Class I new drug registration of monoclonal antibody agents AK102 and AK109 are underway, with a production capacity of 8,000L established in May 2022[54]. - The Group aims to transform into an innovative drug enterprise by gradually expanding its high-end R&D system based on the generic drug R&D system[53]. - Research and development expenses increased to RMB 29,960,000, up by RMB 1,815,000 compared to the same period last year[89]. - The Group obtained a total of 11 approvals for 9 varieties during the period, including 2 approvals for supplementary applications[82]. Operational Efficiency - The Group's gross profit increased by 5.1% over the same period last year, indicating improved operational efficiency[49]. - The Group reorganized its structure in July 2022 to enhance operational efficiency and corporate governance, facilitating future bidding opportunities in national centralized procurement[60]. - The Group's marketing department focused on expanding product coverage and maintaining high supply volumes for key products despite external challenges[47]. - The Group's focus on high-quality specialty drug products and robust financial management has enabled it to maintain stable business growth despite intense market competition[57]. Financial Position and Investments - The Group held cash and bank balances of approximately RMB601,576,000 as of June 30, 2022, an increase from RMB577,744,000 as of December 31, 2021[104]. - Net cash flows from operating activities during the period were approximately RMB269,303,000, up from RMB153,202,000 in 2021[104]. - The registered capital of Lanzhou Dawnrays Pharmaceutical Co., Ltd. was increased from USD50,000,000 to USD80,000,000 in May 2022, with the Group holding a 96.875% share interest[106]. - The Group plans to invest RMB430,000,000 in the Lanzhou project, which is expected to be completed and put into production in the second half of 2022[106]. - The company reported a share of losses from an associate amounting to RMB 20,493,000, compared to RMB 17,122,000 in 2021, indicating increased challenges in associated investments[196]. Corporate Governance and Management - The company complied with the Corporate Governance Code during the six months ended June 30, 2022, with one deviation regarding non-executive directors' attendance at the AGM[159]. - Mr. Chen Shaojun resigned as executive director and CEO effective February 16, 2022, to focus on other business[160]. - Mr. Wu Weixian was appointed as the new CEO effective February 16, 2022[160]. - The Audit Committee reviewed the interim financial statements before board approval, ensuring compliance with financial reporting standards[170]. Shareholder Information - As of June 30, 2022, Ms. Li Kei Ling holds 107,372,000 shares directly beneficially owned and has a total interest of 702,100,000 shares, representing 46.85% of the company's issued share capital[139]. - Mr. Hung Yung Lai directly beneficially owns 1,880,000 shares and has a total interest of 596,608,000 shares, accounting for 39.81% of the company's issued share capital[139]. - Fortune United Group Limited, a holding company, holds 594,728,000 shares of the company, with Ms. Li Kei Ling and Mr. Hung Yung Lai each beneficially interested in 50% of its share capital[144].

Financial Performance - The company reported a significant increase in revenue, achieving a total of HKD 1.2 billion, representing a growth of 15% compared to the previous year[11]. - The Group recorded revenue of approximately RMB1,165,155,000 for the year ended 31 December 2021, representing an increase of 13.8% compared to 2020[20]. - Profit attributable to owners of the parent was approximately RMB358,175,000, reflecting a 33.6% increase compared to RMB268,130,000 in 2020[20]. - Operating profit, excluding certain factors, was RMB335,085,000, which is a 16.8% increase from RMB286,901,000 in 2020[20]. - The increase in revenue and operating profit was mainly due to a significant rise in sales volume of products won in the national centralized procurement of drugs[20]. - Gross profit was approximately RMB681,262,000, an increase of RMB130,617,000 or 23.7% compared to last year, with a gross profit margin of 58.5%[87]. - The segment profit from the finished drugs segment was approximately RMB546,252,000, an increase of RMB72,966,000 compared to RMB473,286,000 in 2020[92]. Market Expansion and Product Development - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[11]. - New product launches are expected to contribute an additional HKD 200 million in revenue, with a focus on innovative pharmaceuticals[11]. - The Group plans to increase research and development investment to enrich its product mix, particularly focusing on chronic diseases and children's drugs, in response to market demands from an aging population and government policies[41][44]. - The Group has entered into a product cooperation agreement with Nanjing Han Xin Pharmaceutical Technology Co., Ltd. for the joint research and development of 5 products, aiming to launch several new products in various treatment fields over the next few years[35][37]. - The Group is actively developing new drug products through partnerships with domestic research institutions and has established a joint venture for drug delivery system technology[67]. Operational Efficiency and Cost Management - The gross profit margin improved to 45%, up from 42% in the previous year, due to cost optimization strategies[11]. - The Group is enhancing its production capacity and efficiency, contributing to improved profitability through cost reduction initiatives[75]. - The construction of new factories will incorporate energy-saving and emission-reduction facilities to align with environmental protection policies and the goal of carbon peaking by 2030[40][43]. - The Group's management is enhancing oversight to mitigate operational risks associated with the relocation of production facilities[36][38]. Dividends and Shareholder Returns - A dividend of HKD 0.10 per share was declared, reflecting a payout ratio of 30% of net profits[11]. - The Board recommended a final dividend of HK$0.065 per share, totaling approximately HK$97,392,000, which is an increase from HK$74,813,000 in 2020[22]. - The total annual dividend distributed for the year will be HK$0.08 per share, with an annual dividend payout ratio of approximately 27.3%, a decrease of 3.6 percentage points year-on-year[23]. Research and Development - Clinical trials for new drug registrations of monoclonal antibodies are ongoing, with the Group remaining cautiously optimistic about the investment prospects[30]. - The Group is conducting clinical trials for two monoclonal antibody drugs, AK102 and AK109, with AK102 in Phase III and AK109 in Phase I trials, maintaining a cautiously optimistic outlook on these investments[33]. - The Group applied for the registration of a total of 15 varieties in 2021, including 7 supplementary applications for consistency evaluation and 4 Class 4 chemical medicines[76]. - The Group obtained 2 drug production approvals, 3 consistency evaluation approvals, and 2 supplementary application approvals in 2021[76]. Risk Management and Internal Controls - The Group's internal control system is designed to safeguard assets against misappropriation and unauthorized disposition, managing operational risks effectively[180]. - The risk management framework includes identifying significant risks, developing measures to mitigate them, and monitoring their effectiveness[180]. - The internal audit department reviews major operational and financial controls, reporting directly to the Chairman and the Audit Committee[181]. - The internal audit aims to cover all major operations of the Group on a rotational basis, ensuring compliance with established processes and standards[181]. Corporate Governance - The Board currently comprises six Directors: two Executive Directors, one Non-executive Director, and three Independent Non-executive Directors, meeting the requirement of at least one-third being Independent[151]. - The Company has established a governance framework to ensure compliance with applicable rules and regulations, including the handling of conflicts of interest[150]. - The Company adopted a Board Diversity Policy to enhance diversity at the Board level, considering factors such as ethnicity, experience, and professional skills[197]. - The Nomination Committee is responsible for reviewing the Board's structure and composition at least annually and making recommendations for changes to align with the Company's corporate strategy[195].

Financial Performance - The Group recorded revenue of approximately RMB 608,589,000 for the six months ended 30 June 2021, representing an increase of 24.5% compared to RMB 488,993,000 in the same period of 2020[32]. - Profit attributable to owners of the parent was approximately RMB 166,646,000, reflecting an increase of approximately 28.5% compared to RMB 129,691,000 in the same period of 2020[32]. - The Group experienced a year-on-year revenue and profit growth during the period, reflecting a double-digit percentage increase compared to the same period last year[40][44]. - For the six months ended June 30, 2021, the Group recorded a turnover of approximately RMB 608,589,000, representing an increase of 24.5% compared to RMB 488,993,000 during the corresponding period of last year[81]. - Gross profit was approximately RMB 373,091,000, which increased by RMB 108,355,000 or 40.9% compared to the corresponding period of last year, with a gross profit margin of 61.3%[81]. - The profit attributable to owners of the parent for the six months ended June 30, 2021, was approximately RMB 166,646,000, reflecting an increase of RMB 36,955,000 or 28.5% year-on-year[91]. - Profit before tax increased to RMB 211,082,000, representing a 30.2% rise from RMB 161,905,000 in 2020[167]. - Profit for the period was RMB 165,691,000, a 30% increase compared to RMB 127,552,000 in 2020[171]. - Basic earnings per share for the period was RMB 0.11127, compared to RMB 0.08362 in 2020, reflecting a 33.2% increase[167]. Sales and Product Performance - The increase in profit was mainly due to the rise in sales of main products of finished drugs[32]. - The marketing and sales department expanded product coverage, leading to increased sales volume and revenue in major sectors of finished drugs compared to the previous year[34]. - Major products such as Amlodipine Besylate Tablets and Losartan Potassium Tablets experienced expected growth in sales due to effective use of brand advantages and marketing resources[34]. - Sales volume of the "An" series anti-hypertensive drugs increased by 38.5%, with sales revenue rising by 24.0% compared to the same period in 2020[57][61]. - The Fujian Dawnrays series medicines, primarily for treating hyperlipidemia, saw a sales volume increase of 92.6% and a revenue increase of 85.4% year-on-year[57][61]. - Sales volume of anti-allergic drugs "Xikewei" and "Xikexin" increased by 35.5%, with sales revenue growing by 47.6% compared to the same period last year[57][61]. - The sales volume of Entecavir Dispersible Tablets increased by 95.7%, with a revenue increase of 38.5% year-on-year[57][61]. - Sales of finished drugs amounted to RMB 531,119,000, representing an increase of RMB 149,435,000, or 39.2% compared to the corresponding period of last year[81]. - The sales amount of finished drugs accounted for approximately 87.3% of total sales, representing an increase of 9.2 percentage points compared to last year[81]. Research and Development - The Group is actively progressing with clinical trials for monoclonal antibody agents Ebronucimab (AK102) and A.K109, aimed at treating various conditions[42][45]. - The Group plans to continue investing in production technology and product R&D to strengthen its product structure and profitability foundation[60]. - The Group is engaged in R&D projects covering therapeutic areas including the circulatory system, digestive system, endocrine system, ophthalmology, dermatology, and antiviral drugs[63]. - As of June 30, 2021, the Group conducted quality and efficacy research on 31 varieties, with applications for 6 varieties approved and 10 varieties submitted for consistency evaluation[69]. - The Group is researching 22 new varieties and developing bulk medicines for 14 of them, with 3 submitted for application and 19 under R&D[72]. - The Group established a joint venture, Nanjing PharmaRays, to enhance its R&D capabilities focusing on new drug products using advanced drug delivery systems[67]. Financial Position and Cash Flow - As of June 30, 2021, the Group held cash and bank balances of approximately RMB571,815,000, a decrease from RMB730,986,000 as of December 31, 2020[101]. - The Group recorded net cash flows from operating activities of approximately RMB153,202,000 for the period, compared to RMB138,285,000 in 2020[101]. - The Group's short-term interest-bearing bank borrowings were RMB9,245,000 as of June 30, 2021, with a debt ratio of 0.3%[101]. - The Group's inventory balance was approximately RMB212,780,000 as of June 30, 2021, down from RMB246,028,000 as of December 31, 2020[101]. - The company reported a net decrease in cash and cash equivalents of RMB (78,657,000) for the period, compared to RMB (72,224,000) in the previous year[195]. Corporate Governance and Shareholder Information - The company has complied with the Corporate Governance Code during the six months period ended June 30, 2021[156]. - The Audit Committee reviewed the unaudited interim condensed consolidated financial statements for the six months ended June 30, 2021, before recommending them to the Board for approval[164]. - The record date for determining shareholders' entitlement to the interim dividend is September 24, 2021[164]. - The company has not granted any rights to acquire shares or debentures to any Director during the period[138]. - Ms. Li Kei Ling holds 698,756,000 shares, representing 46.68% of the Company's issued share capital[133]. - Mr. Hung Yung Lai holds 593,264,000 shares, representing 39.63% of the Company's issued share capital[133]. - The company repurchased 8,608,000 shares of its listed securities at an aggregate consideration of HK$11,442,400 before expenses during the six months ended June 30, 2021[150].